Open AccessAbstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC
Author(s) -
Sebastian Michels,
Lucia Nogová,
Matthias Scheffler,
Barbara Deschler-Baier,
Martin Sebastian,
Martin Schüler,
Martin Wermke,
Enriqueta Felip,
Rafael Rosell,
D. Rodríguez Abreu,
Diana S.Y. Abdulla,
Rieke Fischer,
Sophia Koleczko,
Anna Kron,
Richard Riedel,
Jan-Philipp Weber,
Jana Fassunke,
Sabine MerkelbachBruse,
Heinz Haverkammp,
Martin Hellmich,
Reinhard Büttner,
Jürgen Wolf
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct255
Subject(s) - medicine , t790m , trametinib , osimertinib , oncology , clinical endpoint , non small cell lung cancer (nsclc) , clinical trial , cancer , epidermal growth factor receptor , lung cancer , erlotinib , mapk/erk pathway , kinase , gefitinib , biology , a549 cell , microbiology and biotechnology